Lineage Cell Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Lineage Cell Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Lineage Cell Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Lineage Cell Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lineage Cell Therapeutics Inc (Lineage) formerly BioTime Inc, is a clinical-stage biotechnology that develops new cell therapies for unmet medical needs. It develops products based on its core proprietary technology cell-based therapy platform. The company focuses on developing new cellular therapies for neurological conditions associated with demyelination and degenerative retinal diseases. Lineage's major products include OpRegen, a cell therapy program for the treatment of ocular disorders, and OPC1, a cell therapy designed to improve recovery following a spinal cord injury. The company has an operational presence in the US and operates a manufacturing facility in Jerusalem, Israel. Lineage is headquartered in Carlsbad, California, the US.
Headquarters
United States of America
Address
2173 Salk Avenue, Suite 200, Carlsbad, California, 92008
Website
www.lineagecell.com
Telephone
1 510 5213390
No of Employees
72
Industry
Medical Equipment
Ticker Symbol & Exchange
LCTX (AFM)
Revenue (2025)
$14.6M
53.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-241.4%
(2025 vs 2024)
Market Cap*
$321.6M
Net Profit Margin (2025)
XYZ
-122.8%
(2025 vs 2024)
* As of and is in US$
Lineage Cell Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Cell/Drug Delivery | Renevia |
| Renevia: | HyStem |
| Facial Lipoatrophy | OpRegen |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In August, the company entered into a research collaboration with William Demant Invest A/S (WDI), to Develop ReSonance (ANP1) for hearing loss. |
| 2024 | Contracts/Agreements | In May, the company entered into an agreement with Genentech to support ongoing development of the OpRegen program. |
| 2024 | Regulatory Approval | In February, the company received clearance from the US FDA of its Investigational New Drug amendment (INDa) for OPC1, for the treatment of the treatment of spinal cord injury (SCI). |
Competitor Comparison
| Key Parameters | Lineage Cell Therapeutics Inc | AbbVie Inc | Bayer AG | Novo Nordisk AS | Regeneron Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Germany | Denmark | United States of America |
| City | Carlsbad | North Chicago | Leverkusen | Bagsvaerd | Tarrytown |
| State/Province | California | Illinois | Nordrhein-Westfalen | - | New York |
| No. of Employees | 72 | 57,000 | 92,815 | 68,669 | 15,410 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael H. Mulroy | Chairman | Executive Board | 2024 | 59 |
| Brian M. Culley | Chief Executive Officer; Director | Executive Board | 2018 | 53 |
| Jill A. Howe | Chief Financial Officer | Senior Management | 2022 | 49 |
| Rami Skaliter, Ph.D. | Chief Executive Officer - Cell Cure Neurosciences | Senior Management | 2017 | - |
| Michael Lauw | Vice President - Clinical Development | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer